Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 9/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13588144 | 1.00 | VDR (0.34) | VDRCYP19A1SREBF1MAPTSMN1; SMN2 | |
| SCHEMBL3260530 | 1.00 | VDR (0.34) | VDRCYP19A1SREBF1MAPTSMN1; SMN2 | |
| SCHEMBL3260426 | 1.00 | VDR (0.34) | VDRCYP19A1SREBF1MAPTSMN1; SMN2 | |
| SCHEMBL3260431 | 1.00 | VDR (0.34) | VDRCYP19A1SREBF1MAPTSMN1; SMN2 | |
| SCHEMBL13392819 | 1.00 | VDR (0.34) | VDRCYP19A1SREBF1MAPTSMN1; SMN2 | |
| SCHEMBL3300907 | 1.00 | VDR (0.34) | VDRCYP19A1SREBF1MAPTSMN1; SMN2 | |
| SCHEMBL13392980 | 1.00 | VDR (0.34) | VDRCYP19A1SREBF1MAPTSMN1; SMN2 | |
| SCHEMBL4142595 | 0.94 | VDR (0.31) | VDRCYP19A1 | |
| SCHEMBL13393157 | 0.94 | VDR (0.31) | VDRCYP19A1 | |
| SCHEMBL13393269 | 0.94 | VDR (0.31) | VDRCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093675-A1 | NOVEL METHOD | BIOXELL S.P.A. (IT) | 2010-04-15 | — | — | US | disclosed |
| US-20090298799-A1 | Methods of Treating Osteoporosis and Secondary Hyperparathyroidism Using 20-Methyl, Gemini Vitamin D3 Compounds | BIOXELL S.P.A. (IT) | 2009-12-03 | — | — | US | disclosed |
| US-20090099140-A1 | 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof | BIOXELL S.P.A. (IT) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298799-A1 | Methods of Treating Osteoporosis and Secondary Hyperparathyroidism Using 20-Methyl, Gemini Vitamin D3 Compounds | PTH1R, VDR, CYP24A1 | VDR 2/4885CYP19A1 738/4885SREBF1 778/4885 |
| US-20100093675-A1 | NOVEL METHOD | GC, VDR, CYP24A1 | VDR 2/4885CYP19A1 2283/4885SREBF1 707/4885 |
| US-20090099140-A1 | 20-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof | VDR, CYP24A1, CYP2R1 | VDR 1/4885CYP19A1 141/4885SREBF1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.